Quantcast

Latest Anti-diabetic drugs Stories

2014-09-24 23:02:01

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer. New York, New York (PRWEB) September 24, 2014 Byetta lawsuits(http://www.byettalawsuit.com) and other product liability claims that allege incretin mimetic Type 2 diabetes medications caused patients to develop pancreatic cancer continue to move forward in U.S. courts, Bernstein Liebhard LLP...

2014-09-24 08:28:57

SAN DIEGO, Sept. 24, 2014 /PRNewswire/ -- Freedom Meditech, Inc. today announced the appointment of Daniel M. Bradbury as chairman of the board of directors. Mr. Bradbury is the managing member of BioBrit, LLC, and former CEO of Amylin Pharmaceuticals, Inc. "Mr. Bradbury comes to us with extensive leadership experience in the diabetes space," said Keith Ignotz, CEO of Freedom Meditech. "Mr. Bradbury's insight brings tremendous value in the early stages of market adoption for the...

2014-09-18 20:22:43

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Trulicity(TM) (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY) treatment option for adults with type 2 diabetes. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2...

2014-09-17 12:27:46

SGLT-2 Inhibitors Will Be the Fastest-Growing Drug Class Over the 2013-2023 Forecast Period, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that as physicians continue to adopt a more individualized approach to patient care, branded type 2 diabetes therapies continue to experience increased use despite attempts by payer and reimbursement authorities to limit use of these more expensive drugs. As the robust...

2014-09-17 08:29:46

- Data indicate 58% non-adherence to second-line treatments in T2D patients, significantly higher than patients report and prescribers perceive VIENNA, Sept. 17, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of non-adherence in type 2 diabetes therapies at the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD). In a poster session today, Christian...

2014-09-15 12:24:19

Proven Benefit in Specific Subgroups Will Be a Key Market Access Lever in Crowded Drug Classes, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 15, 2014 /PRNewswire/ -- Decision Resources Group finds that as the type 2 diabetes treatment armamentarium continues to expand, increasing pressure to control expenditures will result in mounting prescribing constraints for premium-priced agents. Interviewed payers emphasize that although type 2 diabetes drugs will...

2014-09-11 23:01:20

The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2 diabetes drug. New York (PRWEB) September 11, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and legal claims involving other incretin mimetic Type 2 diabetes drugs, including Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District...

2014-09-11 16:28:19

- Oral presentation 9/19: interim Phase 3 results for ITCA 650 among patients with high baseline (HBL) HbA1c levels between 10-12% showed dramatic HbA1c reductions, even in patients with high HbA1c despite multi-drug therapy BOSTON, Sept. 11, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced its participation in the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place in Vienna September 15 -19. Intarcia's lead product...

2014-09-03 16:29:02

Takeda Stresses Continued Confidence in ACTOS DEERFIELD, Ill. and OSAKA, Japan, Sept. 3, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that judgment was entered on the jury verdict that was returned on April 7, 2014, in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al. (U.S. Dist. Ct., W. Dist. of Louisiana, Case No. 12-0064). The court...

2014-08-30 23:02:07

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New York, New York (PRWEB) August 30, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and Bydureon (an extended-release...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related